Skip to main content
Clinical Trials/NCT02122549
NCT02122549
Completed
Not Applicable

Hospital Wearable Defibrillator Inpatient Study

Zoll Medical Corporation0 sites59 target enrollmentApril 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
In-Hospital Cardiac Arrest
Sponsor
Zoll Medical Corporation
Enrollment
59
Primary Endpoint
Percentage of Time Rhythm Monitoring by the HWD1000 is Compromised Due to ECG Noise.
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

This study will obtain device-human interaction evaluations for the HWD1000 within the controlled environment of the hospital as well as establish that the safety profile is similar to outpatient wearable cardioverter-defibrillators use.

Detailed Description

A multi-center prospective study of hospitalized patients whom a physician deems at risk of sudden cardiac arrest during the hospitalization period, wearing the HWD1000 hospital wearable defibrillator in order to evaluate caregiver and patient interactions with the device. In addition, ECG signal quality will be reviewed to confirm the HWD1000 safety profile.

Registry
clinicaltrials.gov
Start Date
April 2014
End Date
July 2015
Last Updated
8 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients whom a physician deems at risk of sudden cardiac arrest during the hospitalization period (patients will be monitored using the hospital's telemetry system). Specific inclusion criteria are:
  • Hospitalized patients having continuous independent ECG monitoring.
  • Patients at risk of sudden cardiac arrest during the hospitalization period as determined by the investigating physician.
  • Patient ≥18 years of age (over the legal age of providing consent).

Exclusion Criteria

  • Patients with an active implantable cardioverter-defibrillator.
  • Patients with an active unipolar pacemaker.
  • Patients with physical or mental conditions preventing them from interacting with or wearing the device as determined by the investigating physician.
  • Patients having an advanced directive prohibiting resuscitation.
  • Patients having bandages or other clinical condition preventing the HWD use.
  • Patients unable to consent.
  • Patients having recently experienced an arrhythmic storm.
  • Patients prone to paroxysmal supraventricular tachycardia.

Outcomes

Primary Outcomes

Percentage of Time Rhythm Monitoring by the HWD1000 is Compromised Due to ECG Noise.

Time Frame: 24 hours or longer

The amount of time that the HWD1000 is unable to monitor the subject's rhythm status is the primary safety measure. The specific goals are that average monitoring will be inhibited by noise no greater than 2% of the time worn (at least 24 hours) and monitoring using single lead analysis will be no greater than 5% of the time worn (at least 24 hours).

Similar Trials